Oncostellae SL
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Oncostellae SL - overview
Established
2013
Location
Santiago de Compostela, -, Spain
Primary Industry
Biotechnology
About
Founded in 2013 and based in Santiago de Compostela, Spain, Oncostellae SL is a clinical-stage biopharmaceutical company. The company was founded by Julio Castro. In March 2024, Oncostellae SL raised EUR 500,000 in Series A funding from the Center for Technological & Industrial Development, Noso Capital. As of 2024, the company is led by its CEO, Guido Kurz.
Oncostellae develop small-molecule drugs for use as drugs in oncology and inflammatory/automotive diseases. The firm’s pipeline product portfolio includes OST-122, a drug that targets inflammatory bowel disease (IBD); and OST-499, a drug being developed to treat uterine fibroids and other gynecological conditions. The company plans to use the funds raised in March 2024 to accelerate its research and development of a therapeutic drug.
Current Investors
Inveready Asset Management, Xesgalicia, Unirisco Galicia
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy, Oncology/Cancer Treatment
Website
www.oncostellae.com
Verticals
Manufacturing
Company Stage
Series A
Total Amount Raised
Subscriber access only
Oncostellae SL - financials
| Fiscal Year Ended | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 809 | - | - | - | - | - | - | - | - | - |
| % Revenue Growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| EBITDA (USD) | (11,585.5) | (63,260.7) | (127,109.7) | (102,076.7) | (77,379.5) | (12,119.4) | (34,250.8) | - | - | - |
| Operating Income (USD) | (11,585.5) | (97,665.2) | (192,767.5) | (230,780.2) | (279,621.7) | (291,828.3) | (368,388.3) | - | - | - |
| Operating Margin | (1432.1%) | - | - | - | - | - | - | - | - | - |
| % EBITDA Margin | (1432.1%) | - | - | - | - | - | - | - | - | - |
| NET Income (USD) | 50,132.4 | 47,368.2 | 280,369.2 | 38,180.7 | 96,002.2 | 60,387.4 | (117,899.7) | - | - | - |
| % Net Margin | 6196.8% | - | - | - | - | - | - | - | - | - |
Oncostellae SL - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.